A prospective, single-arm, exploratory study on the efficacy and safety of romiplostim N01 for cancer treatment–induced thrombocytopenia in patients with gastrointestinal cancers.

Authors
Category Primary study
ConferenceAmerican Society of Clinical Oncology (ASCO) Annual Meeting
Year 2026
This article has no abstract
Epistemonikos ID: 5496ca77e16a68047a4f006d8cffcbd155f419a2
First added on: Jun 27, 2026